
Hyeon-Seok Eom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2626273/publications.pdf Version: 2024-02-01



HVEON-SEOK FOM

#	Article	IF	CITATIONS
1	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Research and Treatment, 2023, 55, 325-333.	3.0	2
2	Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide. Korean Journal of Internal Medicine, 2022, 37, 179-189.	1.7	2
3	Guillain-Barré syndrome after vaccination against COVID-19. Lancet Neurology, The, 2022, 21, 117-119.	10.2	27
4	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2022, 6, 3472-3479.	5.2	12
5	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). International Journal of Hematology, 2022, , 1.	1.6	0
6	Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients. Journal of Clinical Apheresis, 2021, 36, 135-142.	1.3	4
7	Comparison of spectra optia and amicus cell separators for autologous peripheral blood stem cell collection. Journal of Clinical Apheresis, 2021, 36, 28-33.	1.3	4
8	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma. Scientific Reports, 2021, 11, 2674.	3.3	6
9	Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Korean Medical Science, 2021, 36, e55.	2.5	2
10	Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. Journal of Korean Medical Science, 2021, 36, e85.	2.5	6
11	Realâ€world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Cancer Communications, 2021, 41, 275-278.	9.2	4
12	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. Current Problems in Cancer, 2021, 46, 100786.	2.0	0
13	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. Cancer Research and Treatment, 2021, , .	3.0	4
14	Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e97-e104.	0.4	2
15	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. Annals of Hematology, 2020, 99, 255-264.	1.8	3
16	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. International Journal of Hematology, 2020, 112, 84-95.	1.6	5
17	Development of an Automated Image Analyzer for Microvessel Density Measurement in Bone Marrow Biopsies. Annals of Laboratory Medicine, 2020, 40, 312-316.	2.5	0
18	Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. Acta Haematologica, 2019, 141, 176-186.	1.4	16

Нуеол-Ѕеок Еом

#	Article	lF	CITATIONS
19	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation, 2018, 24, 923-929.	2.0	10
20	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investigational New Drugs, 2018, 36, 877-885.	2.6	5
21	Nationwide Statistical Analysis of Lymphoid Malignancies in Korea. Cancer Research and Treatment, 2018, 50, 222-238.	3.0	47
22	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2471-2478.	2.0	24
23	Prognostic Implications of Monosomies in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 159-164.e2.	0.4	10
24	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Cancer Medicine, 2017, 6, 100-108.	2.8	5
25	Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 2677-2682.	1.3	7
26	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. American Journal of Hematology, 2017, 92, 1280-1286.	4.1	34
27	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. Blood Research, 2017, 52, 207.	1.3	11
28	A Case of Disseminated Infection with Skin Manifestation due to Non- <i>neoformans</i> and Non- <i>gattii Cryptococcus</i> in a Patient with Refractory Acute Myeloid Leukemia. Infection and Chemotherapy, 2017, 49, 142.	2.3	12
29	Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. Oncotarget, 2017, 8, 74975-74986.	1.8	17
30	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 92171-92182.	1.8	12
31	A Case of Disseminated Infection with Skin Manifestation due to Non- <i>neoformans</i> and Non- <i>gattii Cryptococcus</i> in a Patient with Refractory Acute Myeloid Leukemia. Infection and Chemotherapy, 2017, 49, 142.	2.3	Ο
32	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Research, 2016, 51, 193.	1.3	6
33	Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications. Radiation Oncology Journal, 2016, 34, 193-201.	1.5	8
34	Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors. Journal of Immunotherapy, 2016, 39, 140-148.	2.4	16
35	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. Annals of Hematology, 2016, 95, 1491-1501.	1.8	9
36	Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 527-535.e2.	0.4	23

Нуеол-Ѕеок Еом

#	Article	IF	CITATIONS
37	Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. Leukemia and Lymphoma, 2016, 57, 1389-1397.	1.3	6
38	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia and Lymphoma, 2016, 57, 1406-1412.	1.3	4
39	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. Oncotarget, 2016, 7, 72033-72043.	1.8	14
40	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood, 2015, 126, 746-756.	1.4	160
41	Longâ€ŧerm followâ€up of imatinib plus combination chemotherapy in patients with newly diagnosed <scp>P</scp> hiladelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2015, 90, 1013-1020.	4.1	37
42	Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. Blood Research, 2015, 50, 204.	1.3	44
43	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. Blood Research, 2015, 50, 7.	1.3	4
44	Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma. Annals of Laboratory Medicine, 2015, 35, 563-569.	2.5	15
45	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. Blood Research, 2015, 50, 160.	1.3	3
46	Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma. Cancer Letters, 2015, 356, 743-750.	7.2	6
47	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Korean Journal of Internal Medicine, 2015, 30, 675-683.	1.7	2
48	Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma. BioMed Research International, 2014, 2014, 1-8.	1.9	62
49	Rapid Sequential Gain of <i>ABL1</i> Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia. Annals of Laboratory Medicine, 2014, 34, 399-401.	2.5	0
50	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Research, 2014, 49, 107.	1.3	10
51	Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma. BioMed Research International, 2014, 2014, 1-8.	1.9	18
52	Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results. Blood, 2014, 124, 2112-2112.	1.4	1
53	Hematopoietic Progenitor Cell Counts Is a Useful Indicator To Determine Appropriate Time For Peripheral Blood Stem Cell Collection. Blood, 2013, 122, 2037-2037.	1.4	0
54	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. Blood, 2013, 122, 55-55.	1.4	4

Нуеол-Ѕеок Еом

#	Article	IF	CITATIONS
55	Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Annals of Hematology, 2012, 91, 223-233.	1.8	11
56	Adverse Prognostic Impact of Vascular Endothelial Growth Factor Gene Polymorphism in Patients with Non-Hodgkin Lymphoma Blood, 2012, 120, 2674-2674.	1.4	0
57	A Retrospective Study to Evaluate the Survival Rates in R-CHOP Chemotherapy Followed by Autologous Stem Cell Transplantation for the Treatment of Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 4517-4517.	1.4	2
	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq0 0 0 rg	BT /Overlocl	10 Tf 50 632 ء 10 Tf
58	High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis Blood, 2012, 120, 3106-3106.	1.4	7
59	Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas. Blood, 2011, 118, 1642-1642.	1.4	2
	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq0 0 0 rg	BT /Overloci	10 Tf 50 557 ع
60	by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. Blood, 2011, 118, 2044-2044.	1.4	19
61	Effects of Prophylactic Defibrotide for Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 4517-4517.	1.4	0
62	Response Assessment Using Early and End-of-Treatment 18F-FLT PET Can Predict Outcome in Patients with Non-Hodgkin Lymphoma,. Blood, 2011, 118, 3679-3679.	1.4	0
63	Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. Blood, 2011, 118, 1990-1990.	1.4	Ο
64	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866.	1.4	0
65	Early Response to Botezomib Combined Chemotherapy Can Be Helpful for Prediction of Progression Free Survival in Patients with Multiple Myeloma Who Were Ineligible for Stem Cell Transplantation. Blood, 2011, 118, 5138-5138.	1.4	0
66	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology, 2010, 89, 489-497.	1.8	12
67	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. International Journal of Hematology, 2010, 92, 52-57.	1.6	41
68	The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study Blood, 2010, 116, 1791-1791.	1.4	2
	Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone,) Tj ETQq1 1 0.784		
69	Blood, 2010, 116, 1765-1765.	1.4	0
70	Prognostic Significance of Immune Thrombocytopenic Purpura In Patients with Malignancy Blood, 2010, 116, 1428-1428.	1.4	0
71	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 27-33.	2.3	9
72	Fluorescent in Situ Hybridization Analysis at Bone Marrow Biopsy Section in Multiple Myeloma Blood, 2009, 114, 4898-4898.	1.4	0

#	Article	IF	CITATIONS
	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE®, Thalidomide,) Tj ETQq1 1 0.78	4314 rgBT	/Overlock 10
73	Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial Blood, 2007, 110, 952-952.	1.4	4
74	A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma Blood, 2007, 110, 3446-3446.	1.4	0